Table 3.

Characteristics of patients with true progression and pseudoprogression

		True Progression	Pseudo-Progression	p-value
		n = 64	n = 14
Treatment group (%)	10 mg Q3 (%)	34 (55.7)	7 ( 50.0)	0.927
	2 mg Q3 (%)	27 (44.3)	7 ( 50.0)	0.927
BOR RECIST (%)*	PD	45 (70.3)	6 ( 42.9)	0.016
	PR	5 ( 7.8)	5 ( 35.7)
	SD	14 (21.9)	3 ( 21.4)
	CR	0 (0.0)	0 (0.0)
Timing after immunotherapy initiation	Delay (months) (mean (SD)	4.57 (3.94)	5.42 (3.52)	0.463
Frequency of imaging beyond initial PD	mean (SD)	2.39 (2.82)	4.93 (4.07)	0.006
	Number of CTs beyond initial PD			0.013
	1 (%)	32 (50.0)	1 ( 7.1)
	2 (%)	15 (23.4)	5 ( 35.7)
	3 (%)	6 ( 9.4)	1 ( 7.1)
	4 (%)	2 ( 3.1)	1 ( 7.1)
	5+ (%)	9 ( 14.1)	6 ( 42.9)
Cause of progression (%)	New lesion	36 (57.1)	7 ( 50.0)	0.850
	Non-target	33 (52.4)	0 ( 0.0)	0.001
	Target	47 (74.6)	9 ( 64.3)	0.651
	New lesion & Non-target	24 (37.5)	0 ( 0.0)	0.015
	New lesion & Target	23 (35.9)	2 ( 14.3)	0.209
	Non target & Target	25 (39.1)	0 ( 0.0)	0.012
	New lesion & Non-target & Target	17 (26.6)	0 ( 0.0)	0.068
Site of PD (%)	Lymph node	40 (62.5)	8 (57.1)	0.944
	Lung	18 (28.1)	3 ( 21.4)	0.858
	Subcutaneous and soft tissue	14 (21.9)	2 ( 14.3)	0.786
	Liver	10 (15.6)	4 ( 28.6)	0.448
	Adrenal	9 (14.1)	0 ( 0.0)	0.303
	Spleen	6 ( 9.4)	1 ( 7.1)	1.000
	Bone	2 ( 3.1)	0 ( 0.0)	1.000

^*BOR from baseline until the time point when true progression or pseudoprogression was encountered.